Cumberland Pharmaceuticals (CPIX) investor relations material

Executive summary

• Completed a $100 million strategic transaction with Apotex Health, divesting all FDA-approved branded products and U.S. commercial operations, with over 99% shareholder approval, and received an additional $11 million for inventory and transition services.

• Transitioned to a development-stage biopharmaceutical company focused on advancing the proprietary ifetroban pipeline for rare diseases and unmet medical needs, retaining majority ownership in Cumberland Emerging Technologies.

• Declared and paid a special $1.50 per share cash dividend, totaling $22–$22.5 million, and authorized a $5 million share repurchase program.

• Retired the $5.2 million bank line of credit, reducing liabilities and maintaining significant liquidity post-transaction.

• Shifted focus and resources to clinical development and early-stage programs, with positive clinical milestones in DMD, SSc, IPF, and oncology.

Financial highlights

• Net revenue from continuing operations was $166,458–$0.2 million for Q2 2026, with a net loss from continuing operations of $3.1 million and a total net loss of $4.1 million including discontinued operations.

• As of June 30, 2026, total assets were $62.9–$63 million, with $3.9–$4 million in cash and cash equivalents, liabilities of $45.8–$46 million, and shareholders’ equity of $17–$17.1 million.

• Discontinued operations generated $8.6 million in Q2 2026 revenue, with a net loss of $1.2 million.

• Received $100 million at transaction closing, with estimated net proceeds of $108 million after taxes and additional payments.

• Declared a special dividend of $1.50 per share, totaling $22–$22.5 million.

Outlook and guidance

• Proceeds from the Apotex transaction and inventory reimbursement are expected to fund operations and product development for at least 12 months, with over $50 million in reserves for unexpected expenses or opportunities.

• Focus is on advancing ifetroban clinical programs in Duchenne muscular dystrophy, systemic sclerosis, idiopathic pulmonary fibrosis, and oncology, with additional CET pipeline candidates in early development.

• No product revenue is expected from continuing operations in the near term; ongoing operating losses are anticipated as investment in R&D continues.

• Investors are encouraged to evaluate progress based on clinical pipeline advancement and capital management.